Maraviroc NDC 72319-025

NDC codes

FDA NDC Directory

Product NDC (as listed)72319-025Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72319-0025Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72319-025-02	72319002502	60 TABLET, FILM COATED in 1 BOTTLE (72319-025-02)Marketed from Sep 15, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Maraviroc
Generic name (nonproprietary): maraviroc
Active ingredients: Maraviroc — 300 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: i3 Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217114
Marketing start: Sep 15, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Chemokine Co-receptor 5 Antagonists (Mechanism)
Identifiers: Product ID 72319-025_0416607a-fd74-87e3-e063-6294a90ae6b5SPL ID 0416607a-fd74-87e3-e063-6294a90ae6b5SPL set ID f7b9c67b-10c6-45b5-b2a8-952cd350b0b1RxCUI 728223, 728225UNII MD6P741W8AUPC 0372319024023, 0372319025020
Pharmacologic class: CCR5 Co-receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472319002502 followed by a unit qualifier and the quantity

Package 72319-0025-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 18, 2023. This label includes a boxed warning.

Indications (excerpt from the label)

Maraviroc is indicated in combination with other antiretroviral agents for the treatment of only CCR5‑tropic human immunodeficiency virus type 1 (HIV‑1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg. Limitations of Use Maraviroc is not recommended in patients with dual/mixed- or CXCR4-tropic HIV- 1 [see Microbiology (12.4) ] . Maraviroc is a CCR5 co-receptor antagonist indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic HIV-1 infection in adults and pediatric patients 2 years of age and older weighing at least 10 kg. ( 1 ) Limitations of Use: • Not recommended in patients with dual/mixed- or CXCR4-tropic…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 217114

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217114
Product	Strength	Form · route	Labeler	Product NDC
Maraviroc	Maraviroc 150 mg/1	Tablet, Film coatedOral	A2A Integrated Pharmaceuticals	73141-024
Maraviroc	Maraviroc 300 mg/1	Tablet, Film coatedOral	A2A Integrated Pharmaceuticals	73141-025
Maraviroc	Maraviroc 150 mg/1	Tablet, Film coatedOral	i3 Pharmaceuticals, LLC	72319-024
Maraviroc	Maraviroc 150 mg/1	Tablet, Film coatedOral	A-S Medication Solutions	50090-8010